Go back
“After a generalist investment experience, I can really appreciate the strength of a sector-focused approach. It allows us to take better decisions regarding sector prioritization and to better support Management teams. We also can afford to take long term investment decisions regarding capacity expansion, GMP facilities’ building or innovation since we have a clear understanding about the major value creation drivers.”
Igor Petricca is a Partner at ARCHIMED.
Igor joined ARCHIMED in 2018, bringing in his rich experience of leading transactions in MedTech, In Vitro Diagnostics (IVD), Pharma Services and Consumer Health, both in Europe and North America. In 2022, he was appointed as a Partner.
Igor started his career at Mediobanca, an Italian investment bank, in the Principal Investing Department. He subsequently worked for seven years at Wise SGR, a Milan based Private Equity firm targeting mid-cap companies where he was contributed to several transactions including IPO’s, leverage buy outs and growth capital deals.
Igor currently holds board positions with an Italy-based manufacturer of aesthetic medicine, GPQ (WiQo), an Italy-based producer of IVD systems, DIESSE, a Canada-based CDMO and formulation development firm, Corealis Pharma Inc. and a US-based provider of consumable electrodes for neurodiagnostic and neurosurgery, Ad-Tech. Igor has led the take-private process of Bomi and numerous exit processes including Primo and Micromed.
PORTFOLIO COMPANIES
